Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women.
A multicentre study covering 69 post-menopausal or oophorectomized women was performed to determine whether Org OD 14 [7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) administered orally in a daily dose of 2.5 mg for 90 consecutive days induces endometrial proliferation. The treatment with Org OD 14 was continued in combination with 1 mg/day of lynestrenol from day 91 for 10 days to ascertain whether secretory transformation of the endometrium and subsequent withdrawal bleeding would occur. Endometrial biopsies were obtained before treatment and on day 91. The effects of Org OD 14 on vaginal mucosa and cervical mucus were also evaluated. Org OD 14 did not display any effect on the endometrium in 56 of the study subjects (83.5%). Weak stimulation (initial proliferation) was seen in 11 of the subjects (16.4%) and withdrawal bleeding occurred in only 5 of these after cessation of the combined treatment with lynestrenol. However, moderate 'oestrogenic' effects on vaginal mucosa and cervical mucus were induced in all study subjects.
D000328:Adult; D001706:Biopsy; D002369:Castration; D002455:Cell Division / Q000187:drug effects; D002584:Cervix Uteri / Q000187:drug effects*; D004341:Drug Evaluation; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D004967:Estrogens / Q000032:analysis; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000494:pharmacology; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009093:Mucus / Q000032:analysis; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000209:etiology; D014621:Vagina / Q000187:drug effects*; D014626:Vaginal Smears
D004967:Estrogens; D009652:Norpregnenes; C027385:tibolone; D008234:Lynestrenol